Mylan Ireland Ltd patents expiration
1. Miacalcin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5733569 | MYLAN IRELAND LTD | Galenic compositions comprising calcitonin and their use |
Mar, 2015
(9 years ago) | |
| US5759565 | MYLAN IRELAND LTD | Galenic compositions comprising calcitonin and their use |
Mar, 2015
(9 years ago) | |
Drugs and Companies using CALCITONIN SALMON ingredient
Market Authorisation Date: 17 August, 1995
Treatment: Nasal administration
Dosage: SPRAY, METERED;NASAL
MIACALCIN family patents
2. Yupelri patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7585879 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months from now) | |
| US7910608 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months from now) | |
| US7288657 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Dec, 2025
(1 year, 7 months from now) | |
| US9765028 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
| US10550081 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
| US11858898 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
| US8541451 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Aug, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7521041 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months from now) | |
| US10106503 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months from now) | |
| US10343995 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months from now) | |
| US8053448 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months from now) | |
| US7491736 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months from now) | |
| US11247969 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months from now) | |
| US8273894 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months from now) | |
| US7550595 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months from now) | |
| US8034946 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(9 months from now) | |
| US11691948 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
| US11008289 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
| US11484531 | MYLAN IRELAND LTD | Methods for treating chronic obstructive pulmonary disease |
Oct, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 09, 2023 |
Drugs and Companies using REVEFENACIN ingredient
NCE-1 date: 09 November, 2022
Market Authorisation Date: 09 November, 2018
Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: SOLUTION;INHALATION
YUPELRI family patents